MVT-100 not checked
Microvascular Therapeutics, LLC
FollowEvery change as it happens, and a Monday email
Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “After randomization, MVT-100, the experimental drug, is administered via IV infusion or bolus administration and echocardiograms are subsequently obtained.”In the company’s words, NCT03882359 on ClinicalTrials.gov
- Tested for
- Heart Diseases
- Main trialPhase 1/2
- “Definity (perflutren lipid microspheres, Lantheus Medical Imaging) is an ultrasound contrast indicated for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border. MVT-100 (the investigational pharmaceutical) is similar to Definity, with the exception of the removal of one lipid in the lipid blend and substitution of another lipid. This study is intended to evaluate the safety and efficacy of MVT-100 using a single ascending dose design in healthy volunteers. Patients are randomized to…”In the company’s words, NCT03882359 on ClinicalTrials.gov
- Copy of
- Definity (Lantheus Medcl)Tested side by side with the original in NCT03882359
Other drugs for Heart Diseases
- MilvexianJohnson & Johnson (Janssen) · Bristol Myers Squibb · Phase 3
- VicagrelJiangsu vcare pharmaceutical technology co., LTD · Phase 3
- T89Tasly · Phase 3
- SotagliflozinLexicon Pharmaceuticals · Phase 3
- CenvacibartRegeneron · Phase 3
- REGN9933Regeneron · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Completed | 30 Sep 2024 | An Ascending Dose Comparison of MVT-100 to Definity in Healthy Volunteers |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026